FDA warns of potential drug interaction between remdesivir, hydroxychloroquine

The Food and Drug Administration yesterday said chloroquine phosphate and hydroxychloroquine sulfate could reduce remdesivir’s antiviral activity.

As a result, FDA, citing a non-clinical lab study, does not recommend co-administration of the drugs. The agency yesterday revoked emergency use authorizations for chloroquine and hydroxychloroquine for COVID-19 treatment.